Animal model studies, conducted by the inventors, have shown that usage of selective agonists of TAAR1, 4,5-dihydro-oxazol-2-ylamine derivatives, can be effective in reducing overall motivation to consume alcohol. It can therefore be used for regular administration, e.g. to prevent alcoholism, help reduce alcohol consumption or recover from alcohol dependence, or to treat already developed alcohol disease. Patent claims cover the deneral formula of 4,5-dihydro-oxazol-2-ylamine and its  use in  treating or preventing alcohol use disorder by reducing alcohol consumption and/or motivation to drink alcohol.

Nencki Institute is the sole applicant.

For more information contact Technology Transfer Office.